Angle success with ovarian cancer

Shares in technology investment firm Angle rose on Tuesday after it said its Parsortix cell separation device had passed an important milestone.

The firm said that the device could now capture ovarian cancer cells, creating the possibility of developing an effective, non-invasive screening technique to enable the early diagnosis and monitoring of ovarian cancer.

Angle said that ovarian cancer usually had a poor prognosis and the mortality rate was disproportionately high because it lacked any clear early detection or screening test.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

This meant that most cases were not diagnosed until they have reached advanced stages.

"The successful capture and identification of cultured ovarian cancer cells added to blood is significant as it suggests that the Parsortix separation technology may work with all solid tumour cancers," said Angle's Chief Executive, Andrew Newland.

Angle said it had previously demonstrated that Parsortix could capture cultured breast cancer, prostate cancer, lung cancer and colon cancer cells added to blood.

Shares in the firm rose almost 4% following the announcement.